Johnson & Johnson (FRA:JNJ)
Germany · Delayed Price · Currency is EUR | Market Cap | 496.02B +38.7% |
| Revenue (ttm) | 80.06B +6.0% |
| Net Income | 22.78B +90.6% |
| EPS | 9.38 +90.5% |
| Shares Out | n/a |
| PE Ratio | 21.77 |
| Forward PE | 20.80 |
| Dividend | 4.57 (2.22%) |
| Ex-Dividend Date | Nov 25, 2025 |
| Volume | 440 |
| Average Volume | 577 |
| Open | 211.00 |
| Previous Close | 209.20 |
| Day's Range | 204.05 - 211.00 |
| 52-Week Range | 129.00 - 209.20 |
| Beta | n/a |
| RSI | 70.22 |
| Earnings Date | Apr 14, 2026 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription... [Read more]
Financial Performance
In 2025, Johnson & Johnson's revenue was $94.19 billion, an increase of 6.05% compared to the previous year's $88.82 billion. Earnings were $26.80 billion, an increase of 90.56%.
Financial numbers in USD Financial StatementsNews
Arsenal v Leuven: Women’s Champions League – live
⚽ WCL updates from the second leg ( first leg: 0-4) ⚽ Live scores | Follow us on Bluesky | Email Sarah Here is Leuven’s team. Linde Veefkind returns after her suspension saw her miss out in the first...
Johnson & Johnson (JNJ) to Invest Over $1B in Pennsylvania Facility
Johnson & Johnson (JNJ) to Invest Over $1B in Pennsylvania Facility
Johnson & Johnson (JNJ) Expands with $1 Billion Investment in Cell Therapy Facility
Johnson & Johnson (JNJ) Expands with $1 Billion Investment in Cell Therapy Facility
Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturin...
Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment i...
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro ( amivantamab and hyaluronidase-lpuj) as a monotherapy for adults with advanced h...
Vanguard Russell 1000 Value Index Fund Buys 9,423 Shares of Johnson & Johnson (JNJ)
Vanguard Russell 1000 Value Index Fund Buys 9,423 Shares of Johnson & Johnson (JNJ)
Johnson & Johnson (JNJ) Receives Breakthrough Therapy Designation for New Cancer Treatment
Johnson & Johnson (JNJ) Receives Breakthrough Therapy Designation for New Cancer Treatment
Vanguard Global Wellesley Income Fund Sells 1,113 Shares of Johnson & Johnson (JNJ)
Vanguard Global Wellesley Income Fund Sells 1,113 Shares of Johnson & Johnson (JNJ)
J&J's Rybrevant Faspro Granted FDA Breakthrough Therapy Status For Head And Neck Cancer
(RTTNews) - Johnson & Johnson (JNJ) said on Wednesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro as a monotherapy for adu...
Vanguard U.S. Value Factor ETF Sells 19,753 Shares of Johnson & Johnson (JNJ)
Vanguard U.S. Value Factor ETF Sells 19,753 Shares of Johnson & Johnson (JNJ)
Vanguard U.S. Minimum Volatility ETF Buys 24,704 Shares of Johnson & Johnson (JNJ)
Vanguard U.S. Minimum Volatility ETF Buys 24,704 Shares of Johnson & Johnson (JNJ)
Vanguard Global Wellington Fund Sells 8,750 Shares of Johnson & Johnson (JNJ)
Vanguard Global Wellington Fund Sells 8,750 Shares of Johnson & Johnson (JNJ)
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, ...
Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO beyond lung cancer RARITAN, N.J., Feb. 1...
Behind the Scenes of Johnson & Johnson's Latest Options Trends
Financial giants have made a conspicuous bearish move on Johnson & Johnson. Our analysis of options history for Johnson & Johnson (NYSE: JNJ) revealed 15 unusual trades. Delving into the details, we ...
Noteworthy ETF Outflows: IVV, JPM, XOM, JNJ
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P 500 ETF (Symbol: IVV) where we have detected an appro...
Integra LifeSciences Announces Key Executive Leadership Appointments
PRINCETON, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today announced the appointment of Teshtar El...
Johnson & Johnson (JNJ) Gains FDA Nod for Monthly Rybrevant Dosing
Johnson & Johnson (JNJ) Gains FDA Nod for Monthly Rybrevant Dosing
WAYCROSS MANAGED RISK EQUITY FUND Buys 7,100 Shares of Johnson & Johnson (JNJ)
WAYCROSS MANAGED RISK EQUITY FUND Buys 7,100 Shares of Johnson & Johnson (JNJ)
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 217 Shares of Johnson & Johnson (JNJ)
BLUEPRINT ADAPTIVE GROWTH ALLOCATION FUND Buys 217 Shares of Johnson & Johnson (JNJ)
Johnson & Johnson: FDA Approves Monthly Dosing Schedule For RYBREVANT FASPRO
(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved a simplified monthly dosing schedule for RYBREVANT FASPRO or amivantamab and hyaluronidase-lpuj. The milestone builds upon the recent...
Goldman Sachs Large Cap Value Fund Sells 2,049 Shares of Johnson & Johnson (JNJ)
Goldman Sachs Large Cap Value Fund Sells 2,049 Shares of Johnson & Johnson (JNJ)
FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Monthly dosing reduces treatment visits while maintaining established safety and efficacy 1,2 Builds on RYBREVANT FASPRO ™ FDA approval to deliver the simplest and fastest combination regimen for EGFR...